Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 302

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 302
---
 being Nasdaq - listedcompany and potential created from enhanced status. Innovation and Collaboration •Accelerated R&D: Sharing research and resources accelerates innovation in key areas, including diabetes. •Improved Product Development: Unified efforts enhance time -to -marketefficiency. Operational Strengths •Enhanced Infrastructure: Consolidation leads to improved technological and operational frameworks. •Stronger Workforce: Combining teams increases capacity and innovation potential. Competitive Landscape •Industry Leadership: Kadimastem believes that Merger positions the combined company as a leader in its field of regenerative medicine. By harnessing the synergy of cellular therapies and novel therapeutic molecules, the Merger brings innovative approaches to enhance therapeutic outcomes. •Defensive Strategy: Merging reduces vulnerabilities to external threats and competition. Shareholder Value •Enhanced Returns: Improved operational efficiency and revenue generation are expected to drive shareholder value. •Long -TermGrowth: A unified strategy fosters sustainable growth opportunities. •Risk Mitigation: Diversification of products, regions, and customer bases reduces potential risks. 137 Vision and Cultural Alignment •Unified Mission:A shared vision enhances focus on long -termgoals. •Integration Potential: Strong cultural alignment is expected to ensure successful integration post -Merger. The Kadimastem Board believes the Merger’s terms were negotiated to maximize value for its shareholders while positioning the combined company for success in its industry. In evaluating and approving the Merger Agreement and the transactions contemplated thereby, the Kadimastem board of directors considered a variety of factors, including the potential benefits and risks associated with the Merger. The Kadimastem board of directors did not assign relative or specific weights to the individual factors considered, and no single factor was determinative or outweighed any other factors in its decision. The decision of the Kadimastem board of directors to approve the Merger Agreement and the transactions contemplated thereby was made after considering the totality of the information presented and the overall expected benefits of the Merger. In addition to the above factors, the Kadimastem Board also considered several negative factors, including: •Potential issues with synergy, which need to implement and make changes in the R&D team; •Issues relating to culture -baseddifferences between the leadership of NLS and Kadimastem; •Interaction of several geographic location for the company, between Switzerland, Israel and the United States; •Upfront costs of merging systems, rebranding, and restructuring may be substantial; •Initial financial strain from transition costs and restructuring may negatively impact short -